Improving pancreatic cancer diagnosis using circulating tumor cells: Prospects for staging and single-cell analysis

Colin M. Court, Jacob S. Ankeny, Shuang Hou, Hsian Rong Tseng, James S. Tomlinson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Pancreatic cancer (PC) is the fourth most common cause of cancer-related death in the USA, primarily due to late presentation coupled with an aggressive biology. The lack of adequate biomarkers for diagnosis and staging confound clinical decision-making and delay potentially effective therapies. Circulating tumor cells (CTCs) are a promising new biomarker in PC. Preliminary studies have demonstrated their potential clinical utility, and newer CTC isolation platforms have the potential to provide clinicians access to tumor tissue in a reliable, real-time manner. Such a liquid biopsy has been demonstrated in several cancers, and small studies have demonstrated its potential applications in PC. This article reviews the available literature on CTCs as a biomarker in PC and presents the latest innovations in CTC research as well as their potential applications in PC.

Original languageEnglish (US)
Pages (from-to)1491-1504
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number11
DOIs
StatePublished - Nov 2 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Taylor & Francis.

Keywords

  • biomarker
  • circulating tumor cells
  • diagnosis
  • liquid biopsy
  • pancreatic cancer
  • personalized medicine
  • precision medicine
  • single cell sequencing
  • staging

Fingerprint

Dive into the research topics of 'Improving pancreatic cancer diagnosis using circulating tumor cells: Prospects for staging and single-cell analysis'. Together they form a unique fingerprint.

Cite this